Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Retained Earnings (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Retained Earnings for 3 consecutive years, with -$166.4 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Retained Earnings rose 2.61% year-over-year to -$166.4 million, compared with a TTM value of -$166.4 million through Sep 2024, up 2.61%, and an annual FY2023 reading of -$157.6 million, up 3.39% over the prior year.
  • Retained Earnings was -$166.4 million for Q3 2024 at Oramed Pharmaceuticals, down from -$146.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$136.9 million in Q1 2022 and bottomed at -$170.9 million in Q3 2023.
  • Average Retained Earnings over 3 years is -$157.6 million, with a median of -$157.6 million recorded in 2023.
  • The sharpest move saw Retained Earnings decreased 21.56% in 2023, then increased 12.44% in 2024.
  • Year by year, Retained Earnings stood at -$163.1 million in 2022, then grew by 3.39% to -$157.6 million in 2023, then fell by 5.63% to -$166.4 million in 2024.
  • Business Quant data shows Retained Earnings for ORMP at -$166.4 million in Q3 2024, -$146.8 million in Q2 2024, and -$156.0 million in Q1 2024.